These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36594442)

  • 21. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
    Skiadopoulos MH; Surman SR; Riggs JM; Orvell C; Collins PL; Murphy BR
    Virology; 2002 May; 297(1):136-52. PubMed ID: 12083844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.
    Belshe RB; Karron RA; Newman FK; Anderson EL; Nugent SL; Steinhoff M; Clements ML; Wilson MH; Hall SL; Tierney EL
    J Clin Microbiol; 1992 Aug; 30(8):2064-70. PubMed ID: 1323576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
    Skiadopoulos MH; Tao T; Surman SR; Collins PL; Murphy BR
    Vaccine; 1999 Oct; 18(5-6):503-10. PubMed ID: 10519940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.
    Pennathur S; Haller AA; MacPhail M; Rizzi T; Kaderi S; Fernandes F; Bicha L; Schickli JH; Tang RS; Chen W; Nguyen N; Mathie S; Mehta H; Coelingh KL
    J Gen Virol; 2003 Dec; 84(Pt 12):3253-3261. PubMed ID: 14645907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
    Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
    Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
    Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
    Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and epidemiological characteristics of human parainfluenza virus infections of children in southern Taiwan.
    Wu KW; Wang SM; Shen CF; Ho TS; Wang JR; Liu CC
    J Microbiol Immunol Infect; 2018 Dec; 51(6):749-755. PubMed ID: 28757139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Interfering and interferonogenic activity of attenuated and original para-influenza viral strains].
    Shitikov GS; Boldasov VK
    Vopr Virusol; 1977; (4):445-9. PubMed ID: 200011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of parainfluenza virus types 1, 2 and 3 infections based on virus isolation between 2002 and 2011 in Yamagata, Japan.
    Mizuta K; Abiko C; Aoki Y; Ikeda T; Itagaki T; Katsushima F; Katsushima Y; Matsuzaki Y; Noda M; Kimura H; Ahiko T
    Microbiol Immunol; 2012 Dec; 56(12):855-8. PubMed ID: 22946520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
    Kobayashi H; Iwatsuki-Horimoto K; Kiso M; Uraki R; Ichiko Y; Takimoto T; Kawaoka Y
    Vaccine; 2013 Dec; 31(52):6239-46. PubMed ID: 24144478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of vaccines for parainfluenza virus infections.
    Sato M; Wright PF
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.
    Surman SR; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol Methods; 2007 Apr; 141(1):30-3. PubMed ID: 17210187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
    Madhi SA; Cutland C; Zhu Y; Hackell JG; Newman F; Blackburn N; Murphy BR; Belshe RB; Karron RA; Deatly AM; Gruber WC; Bernstein DI; Wright PF
    Vaccine; 2006 Mar; 24(13):2432-9. PubMed ID: 16406170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of laboratory and administrative data to understand the potential impact of human parainfluenza virus 4 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada.
    Fathima S; Simmonds K; Invik J; Scott AN; Drews S
    BMC Infect Dis; 2016 Aug; 16(1):402. PubMed ID: 27514690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.
    Jones B; Zhan X; Mishin V; Slobod KS; Surman S; Russell CJ; Portner A; Hurwitz JL
    Vaccine; 2009 Mar; 27(12):1848-57. PubMed ID: 19200447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for a parainfluenza virus vaccine.
    Ewasyshyn M; Cates G; Jackson G; Scollard N; Symington A; Klein M
    Pediatr Pulmonol Suppl; 1997; 16():280-1. PubMed ID: 9443313
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.